GLP-1 pill aleniglipron achieves 12.1% weight loss in 36-week trial
This digest was compiled by AI from multiple sources — links to the originals are below.
An experimental once-daily GLP-1 pill, aleniglipron, helped adults with obesity lose up to 12.1% of their body weight over 36 weeks in a phase II trial. The small-molecule drug offers an oral alternative to injectable GLP-1s like Wegovy and may be easier to produce at scale.
Small-Molecule Innovation
Aleniglipron is a small-molecule GLP-1 receptor agonist developed for obesity. Unlike peptide-based drugs such as semaglutide (Wegovy/Ozempic), it can be taken orally once daily with or without food. As a small molecule, it is chemically synthesized, potentially allowing for easier combination with other medications and lower manufacturing costs. Robert Kushner, professor emeritus at Northwestern Medicine, noted that most common medications are small molecules, making this a familiar formulation.
Phase II Trial Outcomes
The randomized, double-blind, placebo-controlled trial enrolled 230 adults with obesity or overweight at 38 U.S. medical centers. Participants received once-daily doses of 45 mg, 90 mg, or 120 mg of aleniglipron or placebo for 36 weeks. At the highest dose, average weight loss reached 12.1% from baseline, compared to 10.7% for 90 mg, 9.0% for 45 mg, and 0.5% for placebo. Results were published in Nature Medicine.
Scalability and Access
Peptide-based GLP-1 injections like semaglutide face barriers: cold-chain storage, high production costs, and injection requirements. Aleniglipron’s small-molecule design could enable oral dosing and simpler manufacturing at scale. Kushner suggested this could broaden access to obesity treatment. No severe safety signals were reported, though further studies are needed.
What's Next
The drug’s developer is expected to advance aleniglipron to phase III trials, though no timeline has been announced. It remains unclear whether the oral GLP-1 pill will match the weight loss levels of higher-dose injectables or gain approval amid a crowded obesity drug market.
1 source
GLP-1 pill aleniglipron achieves 12.1% weight loss in 36-week trial
